Abstract
The basis for the extensive variability seen in the reconstitution of CD4+ T cell counts in HIV-infected individuals receiving highly active antiretroviral therapy (HAART) is not fully known. Here, we show that variations in CCL3L1 gene dose and CCR5 genotype, but not major histocompatibility complex HLA alleles, influence immune reconstitution, especially when HAART is initiated at <350 CD4+ T cells/mm3. The CCL3L1-CCR5 genotypes favoring CD4+ T cell recovery are similar to those that blunted CD4+ T cell depletion during the time before HAART became available (pre-HAART era), suggesting that a common CCL3L1-CCR5 genetic pathway regulates the balance between pathogenic and reparative processes from early in the disease course. Hence, CCL3L1-CCR5 variations influence HIV pathogenesis even in the presence of HAART and, therefore, may prospectively identify subjects in whom earlier initiation of therapy is more likely to mitigate immunologic failure despite viral suppression by HAART. Furthermore, as reconstitution of CD4+ cells during HAART is more sensitive to CCL3L1 dose than to CCR5 genotypes, CCL3L1 analogs might be efficacious in supporting immunological reconstitution.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Douek, D.C., Picker, L.J. & Koup, R.A. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 21, 265–304 (2003).
Rodriguez, B. et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. J. Am. Med. Assoc. 296, 1498–1506 (2006).
Dolan, M.J. et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry–independent mechanisms. Nat. Immunol. 8, 1324–1336 (2007).
Moore, R.D. & Keruly, J.C. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin. Infect. Dis. 44, 441–446 (2007).
Grabar, S. et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133, 401–410 (2000).
Tarwater, P.M. et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 27, 168–175 (2001).
Hunt, P.W. et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17, 1907–1915 (2003).
Moore, D.M. et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J. Acquir. Immune Defic. Syndr. 40, 288–293 (2005).
Valdez, H. et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 16, 1859–1866 (2002).
Kaufmann, G.R. et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μl in HIV type 1–infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis. 41, 361–372 (2005).
Podlekareva, D. et al. Factors associated with the development of opportunistic infections in HIV-1–infected adults with high CD4+ cell counts: a EuroSIDA study. J. Infect. Dis. 194, 633–641 (2006).
Mehandru, S. et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 3, e484 (2006).
Deeks, S.G., Barbour, J.D., Martin, J.N., Swanson, M.S. & Grant, R.M. Sustained CD4+ T cell response after virologic failure of protease inhibitor–based regimens in patients with human immunodeficiency virus infection. J. Infect. Dis. 181, 946–953 (2000).
Ledergerber, B. et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1–infected individuals with virological failure to all three antiretroviral drug classes. Lancet 364, 51–62 (2004).
Deeks, S.G. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. J. Am. Med. Assoc. 286, 224–226 (2001).
Kaufmann, G.R. et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch. Intern. Med. 163, 2187–2195 (2003).
Garcia, F. et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J. Acquir. Immune Defic. Syndr. 36, 702–713 (2004).
Tenorio, A.R. et al. HIV-1–infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J. Acquir. Immune Defic. Syndr. 34, 491–496 (2003).
Anastos, K. et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann. Intern. Med. 140, 256–264 (2004).
Grabar, S. et al. Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 39, 284–292 (2005).
Zhang, Z.Q. et al. The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P. Virology 320, 75–84 (2004).
Mellors, J.W. et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126, 946–954 (1997).
Lifson, J.D. et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J. Virol. 74, 2584–2593 (2000).
Nibbs, R.J., Yang, J., Landau, N.R., Mao, J.H. & Graham, G.J. LD78β, a non-allelic variant of human MIP-1α (LD78α), has enhanced receptor interactions and potent HIV suppressive activity. J. Biol. Chem. 274, 17478–17483 (1999).
Gonzalez, E. et al. Race-specific HIV-1 disease–modifying effects associated with CCR5 haplotypes. Proc. Natl. Acad. Sci. USA 96, 12004–12009 (1999).
Mangano, A. et al. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J. Infect. Dis. 183, 1574–1585 (2001).
Gonzalez, E. et al. The influence of CCL3L1 gene–containing segmental duplications on HIV-1/AIDS susceptibility. Science 307, 1434–1440 (2005).
Martin, M.P. et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282, 1907–1911 (1998).
Kaslow, R.A., Dorak, T. & Tang, J.J. Influence of host genetic variation on susceptibility to HIV type 1 infection. J. Infect. Dis. 191 (Suppl 1), S68–S77 (2005).
Carrington, M. & O'Brien, S.J. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54, 535–551 (2003).
Nguyen, L. et al. Frequent human leukocyte antigen class I alleles are associated with higher viral load among HIV type 1 seroconverters in Thailand. J. Acquir. Immune Defic. Syndr. 37, 1318–1323 (2004).
Rauch, A. et al. HLA-Bw4 homozygosity is associated with an impaired CD4-T-cell recovery after initiation of antiretroviral therapy. Clin. Infect. Dis. (in the press).
Brumme, Z.L. et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J. Infect. Dis. 195, 1694–1704 (2007).
Moore, D.M. et al. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 20, 371–377 (2006).
Weber, R. et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch. Intern. Med. 166, 1632–1641 (2006).
Gutierrez, F. et al. Clinical Outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS ONE 1, e89 (2006).
El-Sadr, W.M. et al. CD4+ count–guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283–2296 (2006).
Lewden, C. et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr. 46, 72–77 (2007).
Valdez, H., Purvis, S.F., Lederman, M.M., Fillingame, M. & Zimmerman, P.A. Association of the CCR5Δ32 mutation with improved response to antiretroviral therapy. J. Am. Med. Assoc. 282, 734 (1999).
Yamashita, T.E. et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 15, 735–746 (2001).
Kasten, S. et al. Positive influence of the Δ32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1–infected patients. Eur. J. Med. Res. 5, 323–328 (2000).
O'Brien, T.R. et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 14, 821–826 (2000).
Holmberg, S.D., Palella, F.J., Jr, Lichtenstein, K.A. & Havlir, D.V. The case for earlier treatment of HIV infection. Clin. Infect. Dis. 39, 1699–1704 (2004).
Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1–128 <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGl.pdf>, accessed 29 February 2008 (Department of Health and Human Services, 29 January 2008).
Pahwa, S. Role of common γ chain–utilizing cytokines for immune reconstitution in HIV infection. Immunol. Res. 38, 373–386 (2007).
Hecht, F.M. et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J. Infect. Dis. 194, 725–733 (2006).
Saah, A.J. et al. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. AIDS 12, 2107–2113 (1998).
Kaslow, R.A. et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2, 405–411 (1996).
Tang, J. et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 16, 2275–2284 (2002).
Carrington, M., Nelson, G. & O'Brien, S.J. Considering genetic profiles in functional studies of immune responsiveness to HIV-1. Immunol. Lett. 79, 131–140 (2001).
Acknowledgements
The people and funding agencies that made this work possible are listed in the Acknowledgements section in the Supplementary information online.
Author information
Authors and Affiliations
Contributions
S.K.A., H.K. and M.J.D. conceptualized the research, conducted statistical analyses, analyzed the data and wrote the manuscript. G.C., B.K.A., J.F.C., W.H., R.J.O., V.C.M., J.D., J.E., R.A.C., S.F., J.M., S.S.A., S.G.D., S.L., D.R., and F.M.H. made substantial contributions to conceptual ideas, experimental data, analysis of data, preparation of the manuscript and/or cohort data and development. S.K.A. and M.J.D. directed the study and obtained the funding for the genetic work.
Corresponding authors
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–3, Supplementary Tables 1–4, and Supplementary Methods (PDF 2071 kb)
Rights and permissions
About this article
Cite this article
Ahuja, S., Kulkarni, H., Catano, G. et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals. Nat Med 14, 413–420 (2008). https://doi.org/10.1038/nm1741
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1741
This article is cited by
-
CCL3L3-null status is associated with susceptibility to systemic lupus erythematosus
Scientific Reports (2021)
-
Copy number variation of CCL3L1 among three major ethnic groups in Malaysia
BMC Genetics (2020)
-
Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia
Journal of NeuroVirology (2018)
-
CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans
BMC Infectious Diseases (2013)
-
Functional effects of CCL3L1 copy number
Genes & Immunity (2012)